{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:03:12Z","timestamp":1778860992941,"version":"3.51.4"},"reference-count":64,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cachexia is a metabolic wasting disorder characterized by progressive weight loss, muscle atrophy, fatigue, weakness, and appetite loss. Cachexia is associated with almost all major chronic illnesses including cancer, heart failure, obstructive pulmonary disease, and kidney disease and significantly impedes treatment outcome and therapy tolerance, reducing physical function and increasing mortality. Current cachexia treatments are limited and new pharmacological strategies are needed. Agonists for the growth hormone secretagogue (GHS-R1a), or ghrelin receptor, prospectively regulate the central regulation of appetite and growth hormone secretion, and therefore have tremendous potential as cachexia therapeutics. Non-peptide GHS-R1a agonists are of particular interest, especially given the high gastrointestinal degradation of peptide-based structures, including that of the endogenous ligand, ghrelin, which has a half-life of only 30 min. However, few compounds have been reported in the literature as non-peptide GHS-R1a agonists. In this paper, we investigate the in vitro potential of quinolone compounds to modulate the GHS-R1a in both transfected human cells and mouse hypothalamic cells. These chemically synthesized compounds demonstrate a promising potential as GHS-R1a agonists, shown by an increased intracellular calcium influx. Further studies are now warranted to substantiate and exploit the potential of these novel quinolone-based compounds as orexigenic therapeutics in conditions of cachexia and other metabolic and eating disorders.<\/jats:p>","DOI":"10.3390\/ijms19061605","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T04:03:24Z","timestamp":1527653004000},"page":"1605","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia"],"prefix":"10.3390","volume":"19","author":[{"given":"Cristina","family":"Torres-Fuentes","sequence":"first","affiliation":[{"name":"APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Pastor-Cavada","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0466-4889","authenticated-orcid":false,"given":"Rafael","family":"Cano","sequence":"additional","affiliation":[{"name":"School of Chemistry and the Analytical and Biological Chemistry Research Facility (ABCRF), University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Kandil","sequence":"additional","affiliation":[{"name":"Food for Health Ireland, University College Cork, T12 YT20 Cork, Ireland"},{"name":"Department of Anatomy and Neuroscience, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Shanahan","sequence":"additional","affiliation":[{"name":"School of Chemistry and the Analytical and Biological Chemistry Research Facility (ABCRF), University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Juan","sequence":"additional","affiliation":[{"name":"Plant Biology and Ecology Department, Seville University, 41012 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-6113","authenticated-orcid":false,"given":"Hamdy","family":"Shaban","sequence":"additional","affiliation":[{"name":"Food for Health Ireland, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"McGlacken","sequence":"additional","affiliation":[{"name":"School of Chemistry and the Analytical and Biological Chemistry Research Facility (ABCRF), University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harri\u00ebt","family":"Schellekens","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland"},{"name":"Food for Health Ireland, University College Cork, T12 YT20 Cork, Ireland"},{"name":"Department of Anatomy and Neuroscience, University College Cork, T12 YT20 Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: Understanding the molecular basis","volume":"14","author":"Argiles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/528182a","article-title":"Cachexia: The last illness","volume":"528","author":"Lok","year":"2015","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","article-title":"Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis","volume":"83","author":"Fearon","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: A new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin. Nutr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jcsm.12082","article-title":"Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment","volume":"6","author":"Drescher","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","article-title":"Cancer cachexia, mechanism and treatment","volume":"7","author":"Aoyagi","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cmet.2018.02.008","article-title":"The Homeostatic Force of Ghrelin","volume":"27","author":"Yanagi","year":"2018","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tins.2016.12.003","article-title":"Current Understanding of the Hypothalamic Ghrelin Pathways lncucinc Appetite anc Adiposity","volume":"40","author":"Lopez","year":"2017","journal-title":"Trends Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","article-title":"Ghrelin","volume":"4","author":"Muller","year":"2015","journal-title":"Mol. Metab."},{"key":"ref_11","first-page":"11","article-title":"Peptidyl Hormones of Endocrine Cells Origin in the Gut\u2014Their Discovery and Physiological Relevance","volume":"66","author":"Ceranowicz","year":"2015","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.biocel.2013.07.016","article-title":"Control of food intake and muscle wasting in cachexia","volume":"45","author":"Amitani","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/pr.57.4.1","article-title":"International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function","volume":"57","author":"Davenport","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"ref_14","first-page":"80","article-title":"Endocrine and metabolic activities of a recently isolated peptide hormone ghrelin, an endogenous ligand of the growth hormone secretagogue receptor","volume":"38","author":"Jarkovska","year":"2004","journal-title":"Endocr. Regul."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/gast.2001.22158","article-title":"Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin","volume":"120","author":"Asakawa","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuropharm.2009.06.024","article-title":"Lean mean fat reducing \u201cghrelin\u201d machine: Hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity","volume":"58","author":"Schellekens","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s10147-011-0289-0","article-title":"Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients","volume":"17","author":"Hiura","year":"2012","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0304-3940(03)00789-4","article-title":"Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats","volume":"349","author":"Yasuda","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ctrv.2015.09.002","article-title":"Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist","volume":"41","author":"Esposito","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/eje.0.1500447","article-title":"Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects","volume":"150","author":"Akamizu","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36456","DOI":"10.1038\/srep36456","article-title":"A Novel Non-Peptidic Agonist of the Ghrelin Receptor with Orexigenic Activity In vivo","volume":"6","author":"Pardo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijpharm.2017.11.051","article-title":"Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization","volume":"536","author":"Howick","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","article-title":"Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: Results of a randomized phase 2 trial","volume":"24","author":"Takayama","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: Preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jep.2013.04.039","article-title":"Ghrelin receptor is activated by naringin and naringenin, constituents of a prokinetic agent Poncirus fructus","volume":"148","author":"Jang","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jfda.2015.04.005","article-title":"Identification of biosynthetic intermediates of teaghrelins and teaghrelin-like compounds in oolong teas, and their molecular docking to the ghrelin receptor","volume":"23","author":"Hsieh","year":"2015","journal-title":"J. Food Drug Anal."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/jphp.12010","article-title":"Semagacestat, a gamma-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor","volume":"65","author":"Schellekens","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1016\/j.tet.2015.03.061","article-title":"Access to trifluoromethylated 4-alkoxy-2-pyrones, pyridones and quinolones","volume":"71","author":"Clarke","year":"2015","journal-title":"Tetrahedron"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/chem.201602511","article-title":"Methyl fluorosulfonyldifluoroacetate (MFSDA): An Underutilised Reagent for Trifluoromethylation","volume":"23","author":"Clarke","year":"2017","journal-title":"Chem.-Eur. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1574-6976.2010.00247.x","article-title":"Quinolones: From antibiotics to autoinducers","volume":"35","author":"Heeb","year":"2011","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1039\/C7OB02395B","article-title":"Analogues of Pseudomonas aeruginosa signalling molecules to tackle infections","volume":"16","author":"Reen","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1128\/AAC.00190-16","article-title":"Exploiting Interkingdom Interactions for Development of Small-Molecule Inhibitors of Candida albicans Biofilm Formation","volume":"60","author":"Reen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1039\/c2ob26823j","article-title":"Structure\u2013function analysis of the C-3 position in analogues of microbial behavioural modulators HHQ and PQS","volume":"10","author":"Reen","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1574-6941.2011.01121.x","article-title":"The Pseudomonas Quinolone Signal (PQS), and its precursor HHQ, modulate interspecies and interkingdom behaviour","volume":"77","author":"Reen","year":"2011","journal-title":"FEMS Microbiol. Ecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1016\/j.tetlet.2010.09.013","article-title":"Synthesis of 3-halo-analogues of HHQ, subsequent cross-coupling and first crystal structure of Pseudomonas quinolone signal (PQS)","volume":"51","author":"McGlacken","year":"2010","journal-title":"Tetrahedron Lett."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Torres-Fuentes, C., Theeuwes, W.F., McMullen, M.K., McMullen, A.K., Dinan, T.G., Cryan, J.F., and Schellekens, H. (2014). Devil\u2019s Claw to suppress appetite\u2013ghrelin receptor modulation potential of a Harpagophytum procumbens root extract. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103118"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcp.21109","article-title":"Stimulation by ghrelin of p42\/p44 mitogen-activated protein kinase through the GHS-R1a receptor: Role of G-proteins and beta-arrestins","volume":"213","author":"Camina","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/bph.12361","article-title":"Functionally biased signalling properties of 7TM receptors\u2013opportunities for drug development for the ghrelin receptor","volume":"170","author":"Sivertsen","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"Wilson","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","article-title":"How Ligands Illuminate GPCR Molecular Pharmacology","volume":"170","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/B978-0-12-381296-4.00006-3","article-title":"Ghrelin Receptor: High Constitutive Activity and Methods for Developing Inverse Agonists","volume":"485","author":"Els","year":"2010","journal-title":"Methods Enzymol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1210\/me.2003-0069","article-title":"High constitutive signaling of the ghrelin receptor\u2014Identification of a potent inverse agonist","volume":"17","author":"Holst","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1124\/jpet.107.123141","article-title":"Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities","volume":"322","author":"Liu","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1210\/endo.137.12.8940347","article-title":"MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles","volume":"137","author":"Jacks","year":"1996","journal-title":"Endocrinology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MCO.0b013e328300ecc1","article-title":"Cachexia: Prevalence and impact in medicine","volume":"11","author":"Tan","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/nutrit\/nuw029","article-title":"Use of ghrelin in cachexia syndrome: A systematic review of clinical trials","volume":"74","author":"Mansson","year":"2016","journal-title":"Nutr. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1039\/C5OB00315F","article-title":"A structure activity-relationship study of the bacterial signal molecule HHQ reveals swarming motility in Bacillus atrophaeus","volume":"13","author":"Reen","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1039\/C6OB01930G","article-title":"The requirements at the C-3 position of alkylquinolones for signalling in Pseudomonas aeruginosa","volume":"15","author":"Shanahan","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nrm2803","article-title":"Fine-tuning of GPCR activity by receptor-interacting proteins","volume":"10","author":"Ritter","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"27021","DOI":"10.1074\/jbc.M115.659250","article-title":"Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling","volume":"290","author":"Leyris","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: From simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1073\/pnas.1119881109","article-title":"Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor","volume":"109","author":"Mary","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ramirez, V.T., van Oeffelen, W.E.P.A., Torres-Fuentes, C., Chru\u015bcicka, B., Druelle, C., Golubeva, A.V., van de Wouw, M., Dinan, T.G., Cryan, J.F., and Schellekens, H. (2018). Differential Functional Selectivity and Downstream Signalling Bias of Ghrelin Receptor Antagonists and Inverse Agonists. FASEB J., in press.","DOI":"10.1096\/fj.201800655R"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nmo.12300","article-title":"Ghrelin and motilin receptor agonists: Time to introduce bias into drug design","volume":"26","author":"Sanger","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33442","DOI":"10.1074\/jbc.M114.581397","article-title":"G Protein and beta-arrestin signaling bias at the ghrelin receptor","volume":"289","author":"Evron","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bmcl.2014.11.031","article-title":"New trisubstituted 1,2,4-triazoles as ghrelin receptor antagonists","volume":"25","author":"Blayo","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Toth, K., Slosky, L.M., Pack, T.F., Urs, N.M., Boone, P., Mao, L., Abraham, D., Caron, M.G., and Barak, L.S. (2018). Ghrelin receptor antagonism of hyperlocomotion in cocaine-sensitized mice requires betaarrestin-2. Synapse, 72.","DOI":"10.1002\/syn.22012"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4062\/biomolther.2016.165","article-title":"Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology","volume":"25","author":"Bologna","year":"2017","journal-title":"Biomol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/jo00404a066","article-title":"Meldrum\u2019s acid in organic synthesis. 2. A general and versatile synthesis of beta-keto esters","volume":"43","author":"Oikawa","year":"1978","journal-title":"J. Org. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1605\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:29Z","timestamp":1760195189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["ijms19061605"],"URL":"https:\/\/doi.org\/10.3390\/ijms19061605","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]}}}